Cargando…
Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial
We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow’s milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727171/ https://www.ncbi.nlm.nih.gov/pubmed/29234055 http://dx.doi.org/10.1038/s41598-017-16730-6 |